methyl 1-methyl-4-{[({[({[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1H-pyrrole2-yl)carbonyl]amino}-1H-pyrrole-2-carboxylate | 134985-79-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 1-methyl-4-{[({[({[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1H-pyrrole2-yl)carbonyl]amino}-1H-pyrrole-2-carboxylate
• 英文别名: methyl 1-methyl-4-(1-methyl-4-(1-methyl-4-(1-methyl-4-nitro-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxylate；methyl 1-methyl-4-[[1-methyl-4-[[1-methyl-4-[(1-methyl-4-nitropyrrole-2-carbonyl)amino]pyrrole-2-carbonyl]amino]pyrrole-2-carbonyl]amino]pyrrole-2-carboxylate
• CAS: 134985-79-8
• 化学式: C₂₅H₂₆N₈O₇
• 分子量: 550.531
• InChiKey: YIKUTCRPVXTRCM-UHFFFAOYSA-N

物化性质

• 熔点：
  282.2 °C
• 沸点：
  620.6±55.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  40
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  179
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  methyl 1-methyl-4-{[({[({[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1H-pyrrole2-yl)carbonyl]amino}-1H-pyrrole-2-carboxylate 在 palladium on activated charcoal sodium hydroxide 、 氢气 、 N,N'-二环己基碳二亚胺 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 29.0h， 生成 SL 11055
  参考文献：
  名称：

  新型荧光二霉素类似物的简便合成

  摘要：

  描述了一种带有丹磺酰基荧光团的四种间他霉素类似物的简便合成方法。荧光基团和序列识别元件之间的连接性质对DNA结合后的这些配体的荧光性质产生了显着影响。

  DOI：

  10.1016/s0040-4039(01)01040-1
• 作为产物：
  描述：

  1-甲基-4-硝基吡咯-2-羧酸 在 氯化亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 methyl 1-methyl-4-{[({[({[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-1-methyl-1H-pyrrol-2-yl)carbonyl]amino}-1H-pyrrole2-yl)carbonyl]amino}-1H-pyrrole-2-carboxylate
  参考文献：
  名称：

  Distamycin Analogues without Leading Amide at Their N-Termini − Comparative Binding Properties to AT- and GC-Rich DNA Sequences

  摘要：

  DOI：

  10.1002/1099-0690(200211)2002:21<3604::aid-ejoc3604>3.0.co;2-x

文献信息

• [EN] NOVEL BENZODIAZEPINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE BENZODIAZÉPINE
  申请人：IMMUNOGEN INC

  公开号：WO2010091150A1

  公开（公告）日：2010-08-12

  The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  该发明涉及具有抗增殖活性的新型苯二氮䓬啶衍生物，更具体地涉及具有式(I)和(II)的新型苯二氮䓬啶化合物，其中二氮䓬啶环(B)与杂环环(CD)融合，其中杂环环是双环的或式(III)的化合物，其中二氮䓬啶环(B)与杂环环(C)融合，其中杂环环是单环的。该发明提供了这些化合物的细胞毒性二聚体。该发明还提供了单体和二聚体的结合物。该发明进一步提供了使用该发明的化合物或结合物抑制异常细胞生长或治疗哺乳动物增殖性疾病的有效组合物和方法。该发明还涉及使用该发明的化合物或结合物进行体外、原位和体内诊断或治疗哺乳动物细胞或相关病理条件的方法。
• Redirection of the Transcription Factor SP1 to AT Rich Binding Sites by a Synthetic Adaptor Molecule
  作者：Mathias Bolz、Ute Scheffer、Elisabeth Kalden、Michael W. Göbel

  DOI：10.1002/hlca.202100095

  日期：2021.9

  The ubiquitous transcription factor SP1 binds to a GC rich consensus sequence. Here we describe an adaptor molecule that mediates binding of SP1 to a non-cognate DNA site rich in AT. The adaptor is comprised of a Dervan-type hairpin polyamide with high affinity to an AT rich hexamer duplex. It also carries a 27mer DNA that contains the SP1 consensus sequence. The synthesis and purification of the polyamide-DNA

  无处不在的转录因子 SP1 与富含 GC 的共有序列结合。在这里，我们描述了一种适配器分子，它介导 SP1 与富含 AT 的非同源 DNA 位点的结合。该接头由对富含 AT 的六聚体双链体具有高亲和力的Dervan型发夹聚酰胺组成。它还携带含有 SP1 共有序列的 27 聚体 DNA。报道了聚酰胺-DNA 偶联物的合成和纯化。Pulldown 实验和蛋白质印迹分析证明了接头介导的 SP1 与六聚体双链体 TTGTTA 的结合。
• NOVEL BENZODIAZEPINE DERIVATIVES
  申请人：Li Wei

  公开号：US20100203007A1

  公开（公告）日：2010-08-12

  The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及具有抗增殖活性的新型苯二氮平衍生物，更具体地涉及公式（I）和（II）的新型苯二氮平，其中二氮平环（B）与杂环环（CD）融合，其中杂环环为双环或公式（III）的化合物，其中二氮平环（B）与杂环环（C）融合，其中杂环环为单环。本发明提供这些化合物的细胞毒性二聚体。本发明还提供单体和二聚体的结合物。本发明还提供使用该发明的化合物或结合物抑制异常细胞生长或治疗哺乳动物增殖性疾病的组合物和方法。本发明还涉及使用该化合物或结合物进行哺乳动物细胞的体外、原位和体内诊断或治疗，或相关病理条件的方法。
• Benzodiazepine derivatives
  申请人：Li Wei

  公开号：US08809320B2

  公开（公告）日：2014-08-19

  The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及具有抗增殖活性的新型苯二氮平衍生物，更具体地涉及公式（I）和（II）的新型苯二氮平，其中二氮平环（B）与杂环环（CD）融合，其中杂环环为双环或公式（III）的化合物，其中二氮平环（B）与杂环环（C）融合，其中杂环环为单环。本发明提供了这些化合物的细胞毒性二聚体。本发明还提供了单体和二聚体的结合物。本发明还提供了使用本发明的化合物或结合物用于抑制异常细胞生长或治疗哺乳动物增殖性疾病的组合物和方法。本发明还涉及使用本发明的化合物或结合物进行哺乳动物细胞的体外、原位和体内诊断或治疗，或相关病理条件的方法。
• Facile synthesis of oligopeptide distamycin analogs devoid of hydrogen bond donors or acceptors at the N-terminus: sequence-specific duplex DNA binding as a function of peptide chain length
  作者：Santanu Bhattacharya、Mini Thomas

  DOI：10.1016/s0040-4039(00)00802-9

  日期：2000.7

  The first examples of distamycin analogs, which lack hydrogen bond interactor groups at the N-terminus, have been synthesized. The bispyrrole peptide did not exhibit any detectable binding with double-stranded (ds) DNA. However, all other homologues did bind to ds-DNA strongly, with the binding affinities increasing as a function of the number of repeating pyrrole carboxamide units, implying that a hydrogen bond donor or acceptor atom per se at the N-terminus is not essential for their DNA binding. Studies with poly d(GC) showed that the N-terminal formamide is not a prerequisite for GC binding, contrary to earlier postulations. (C) 2000 Elsevier Science Ltd. All rights reserved.